How to use Mobosetinib/Mobosetinib in special groups

Mobocertinib, as a new type of EGFR exon20 insertion mutation-targeting drug, has played an important role in the treatment of non-small cell lung cancer. However, in clinical application, the safety and effectiveness of medication need to be particularly cautious for special groups such as the elderly, those with abnormal liver and kidney function, pregnant women, and lactating women. Elderly patients are one of the main risk groups for non-small cell lung cancer. Due to their reduced metabolic function and multiple underlying diseases, they are more sensitive to the adverse reactions of mobosetinib, such as gastrointestinal side effects, electrolyte imbalance or fatigue. Therefore, it is recommended that elderly patients undergo a comprehensive assessment before treatment and decide whether to start with a low dose based on tolerance. At the same time, biochemical indicators are tested regularly to monitor the development of adverse reactions.

For patients with impaired hepatic function, special attention should be paid to the pharmacokinetic changes of mobosetinib. This drug is mainly metabolized by the liver's CYP3A4 enzyme system. People with liver insufficiency may increase the drug's blood concentration, thereby aggravating the toxicity. They need to be more vigilant, especially when combined with other metabolic drugs. Although there is currently a lack of systematic research data, for patients with moderate to severe liver damage, it is recommended to use it with caution under the supervision of professional doctors and try to avoid combining it with drugs that strongly inhibit or induce liver enzymes.

In terms of renal function, the urinary excretion ratio of mobosetinib is low, and patients with mild renal insufficiency generally do not need dose adjustment. However, the safety of use in patients with moderate to severe renal insufficiency is not clear, and it is recommended to use it with caution under close monitoring. For pregnant women and women of childbearing age, mobosetinibmay interfere with the fetalEGFR signaling pathway and has potential reproductive toxicity. Therefore, strict contraception should be used during treatment to avoid pregnancy. If the patient becomes pregnant unexpectedly while taking the drug, the drug should be discontinued immediately and professional consultation should be received. It is also not recommended for lactating women because it is not clear whether the drug is excreted through breast milk.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib